The latest price target for BioMarin Pharmaceutical (NASDAQ:BMRN) was reported by B of A Securities on March 11, 2026. The analyst firm set a price target for $85.00 expecting BMRN to rise to within 12 months (a possible 56.19% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for BioMarin Pharmaceutical (NASDAQ:BMRN) was provided by B of A Securities, and BioMarin Pharmaceutical maintained their buy rating.

The last upgrade for BioMarin Pharmaceutical Inc happened on January 20, 2026 when Canaccord Genuity raised their price target to $98. Canaccord Genuity previously had a hold for BioMarin Pharmaceutical Inc.

The last downgrade for BioMarin Pharmaceutical Inc happened on December 3, 2025 when Leerink Partners changed their price target from $82 to $60 for BioMarin Pharmaceutical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioMarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioMarin Pharmaceutical was filed on March 11, 2026 so you should expect the next rating to be made available sometime around March 11, 2027.

While ratings are subjective and will change, the latest BioMarin Pharmaceutical (BMRN) rating was a maintained with a price target of $97.00 to $85.00. The current price BioMarin Pharmaceutical (BMRN) is trading at is $54.42, which is out of the analyst’s predicted range.